moomoo ID:0
Log Out
Log in to access Online Inquiry
commented on a stock09/19/2022 10:37

$WUXI BIO(02269.HK)$ Haitong International believes that the U.S. Biom...

$WUXI BIO(02269.HK)$
Haitong International believes that the U.S. Biomanufacturing Act will have limited impact on WuXi Biologics in the short and medium term. The bank said that WuXi Biologics will maintain rapid growth in revenue and profits in 2022-2023. Revenue growth is expected to be 47% and 37%, respectively, and profit growth is expected to be 47% and 38%, respectively. The company has advantages in emerging technology fields including double antibody and ADC, and the number and proportion of projects have increased. The company's Wuxi plant has been substantially unaffected by UVL.
Moomoo is an app offered by Moomoo Technologies Inc. that provides information about investments. Moomoo Technologies is not an investment adviser or a broker-dealer and it provides neither investment or financial advice nor securities trading services. All contents such as comments and links posted or shared by users of the community are opinions of the respective authors only and do not reflect the opinions, views, or positions of Moomoo Technologies, its affiliates, or any employees of Moomoo Technologies or its affiliates. You are advised to consult a qualified financial or tax advisor for your personal financial planning and tax situations. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.
Sign in to post a comment